Wearable Cardioverter Defibrillator for Heart Failure Treatment
Author Information
Author(s): Kazberuk Małgorzata, Pogorzelski Piotr, Kuźma Łukasz, Kurasz Anna, Róg-Makal Magdalena, Matys Urszula, Tokarewicz Justyna, Kralisz Paweł, Dobrzycki Sławomir
Primary Institution: Medical University of Białystok, Poland
Hypothesis
The study aimed to assess the efficacy of wearable cardioverter-defibrillator (WCD) usage in patients awaiting decision on therapy with implantable cardioverter-defibrillators (ICDs).
Conclusion
The WCD acts as a bridge to therapy and may be particularly beneficial for patients with transient or evolving conditions.
Supporting Evidence
- All patients demonstrated good tolerance and compliance with the LifeVest WCD.
- Patients wore the WCD for an average of 93.1 days, about 22.8 hours per day.
- Six out of ten patients showed improvement in left ventricular ejection fraction (LVEF) and did not require ICD implantation.
Takeaway
The wearable defibrillator helps people with heart problems stay safe while they wait for more permanent treatments.
Methodology
A single-centre retrospective, observational case study focused on indications and usage of WCDs in patients with heart failure.
Limitations
The small number of patients with different indications for WCD therapy limits the generalizability of the findings.
Participant Demographics
Mean age of participants was 49.1 years, with a mix of genders and various heart conditions.
Statistical Information
P-Value
0.04
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website